Coverage
-
October 19, 2023
The U.S. Securities and Exchange Commission has objected to a former pharmaceutical executive's attempt to shake off the agency's first "shadow trading" lawsuit before the case makes it to a jury, arguing proof exists the defendant knew he was committing insider trading when he purchased a competitor's stock.
3 other articles on this case.
View all »